Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Dissecting the Interplay between Primary Central Nervous System Lymphoma Cells and the Microenvironment Using Single-Cell Transcriptomic Analysis

Qianru Zhang, Wenqiang Yan, Lu Sun, Guoqing Han, Qiaoli Wu, Yiran Cui, Bolin Liu, Feng Zhang, Ke Pu, Mingchao Zhang, Xiaobing Zhang, Lugui Qiu, Qingguo Li, Gang An, Yuxuan Liu

Blood (2024) 144 (Supplement 1): 1590.

https://doi.org/10.1182/blood-2024-202680

Published: 2024

Journal Articles

Prior Knowledge Integration Improves Relapse Prediction and Identifies Relapse Associated Mechanisms in Childhood B Cell Acute Lymphoblastic Leukemia

Abhishek Vallabhbhai Koladiya, Astraea Jager, Anthony Culos, Milton Merchant, Yuxuan Liu, Lucille Stuani, Jolanda Sarno, Pablo Domizi, Charles G. Mullighan, Nima Aghaeepour, Sean Bendall, Kara L. Davis

Blood (2023) 142 (Supplement 1): 1603.

https://doi.org/10.1182/blood-2023-187264

Published: 2023

Journal Articles

Enrichment in Metabolic Pathway Activation Corresponds to Immunoglobulin Gene Diversity across B Cell Developmental Stages in B-Lymphoblastic Leukemia

Carol Fries Simpson, Yuxuan Liu, Lucille Stuani, Astraea Jager, Cameron Baker, Diana G. Adlowitz, Philip J Rock, Richard Burack, Kara L. Davis

Blood (2023) 142 (Supplement 1): 2972.

https://doi.org/10.1182/blood-2023-189313

Published: 2023

Journal Articles

Uridine Synthesis Is the Metabolic Vulnerability in Relapse-Associated B-ALL Cells with Active Pre-BCR Signaling

Yuxuan Liu, Haowen Jiang, Lucille Stuani, Jolanda Sarno, Pablo Domizi, Milton Merchant, Dorra Jedoui, Astraea Jager, Min Huang, Norman J. Lacayo, Kathleen M. Sakamoto, Jiangbin Ye, Kara L. Davis

Blood (2023) 142 (Supplement 1): 4340.

https://doi.org/10.1182/blood-2023-186925

Published: 2023

Journal Articles

Single-Cell Proteomic Analysis Defines Metabolic Heterogeneity in Response to Venetoclax in AML

Lucille Stuani, Astraea Jager, Ambrine Sahal, Abhishek Koladiya, Jolanda Sarno, Pablo Domizi, Yuxuan Liu, Veronique De Mas, Christian Recher, Francois Vergez, Jean-Emmanuel Sarry, Kara L. Davis

Blood (2022) 140 (Supplement 1): 1028–1029.

https://doi.org/10.1182/blood-2022-171009

Published: 2022

Journal Articles

Targeting Cell Adhesion Molecules in IDH Mutant Myeloid Malignances

Junhua Lyu, Yuxuan Liu, Yuannyu Zhang, Feng Cai, Giovanni A. Botten, Hui Cao, Pranita Kaphle, Ralph J Deberardinis, Jian Xu

Blood (2022) 140 (Supplement 1): 8704–8705.

https://doi.org/10.1182/blood-2022-168313

Published: 2022

Journal Articles

First-in-Class Histone Acetyltransferase (HAT) Activator, YF2, Modulates Immune Evasion in DLBCL, Enhancing the Effects of Immune Checkpoint Blockade

Brian Estrella, Manuel A Pazos, II, Edd C Ricker, Yun Kyoung Ryu, Ted B. Piorczynski, Yuxuan Liu, Seda Tolu, Jennifer E. Amengual

Blood (2022) 140 (Supplement 1): 358–359.

https://doi.org/10.1182/blood-2022-166929

Published: 2022

Journal Articles

Glucocorticoid-Resistant B-Cell Acute Lymphoblastic Leukemic Cells Can be Targeted By BCR-Signaling Inhibition

Jolanda Sarno, Pablo Domizi, Yuxuan Liu, Milton Merchant, Dorra Jedoui, Astraea Jager, Andrea Biondi, Giuseppe Gaipa, Alessio Felice Bava, Kara L. Davis

Blood (2021) 138 (Supplement 1): 617.

https://doi.org/10.1182/blood-2021-150356

Published: 2021

Journal Articles

Inhibition of Pre-BCR Signaling Mediates a Metabolic Switch in B-Cell Progenitor Acute Lymphoblastic Leukemia

Yuxuan Liu, Lucille Stuani, Dorra Jedoui, Milton Merchant, Astraea Jager, Jolanda Sarno, Charles G. Mullighan, Felix J. Hartmann, Sean Bendall, Kara L. Davis

Blood (2021) 138 (Supplement 1): 615.

https://doi.org/10.1182/blood-2021-145956

Published: 2021

Journal Articles

Histone Acetyltransferase (HAT) Activator, YF2, Modulates the p53:BCL6 Axis and Antigen Presentation in Diffuse Large B-Cell Lymphomas

Brian Estrella, Yuxuan Liu, Edd C Ricker, Manuel A Pazos, II, Jole Fiorito, Elisa Zuccarello, Elisa Calcagno, Barry Honig, Ottavio Arancio, Jennifer E. Amengual

Blood (2021) 138 (Supplement 1): 2254.

https://doi.org/10.1182/blood-2021-151442

Published: 2021

Journal Articles

Elucidating Mechanisms of Acquired Resistance to IDH Inhibition By Saturation Variant Screening of Base-Edited Leukemia Cells

Junhua Lyu, Yuxuan Liu, PhD, Hui Cao, MS, Mingyi Chen, MD PhD, Yazan F. Madanat, MD, Yuannyu Zhang, PhD, Zhimin Gu, PhD, Pranita Kaphle, MS, Kathryn E. Dickerson, MD, Paul Yenerall, PhD, Rahul Kollipara, PhD, Ralf Kittler, PhD, John Minna, MD, Weina Chen, MD PhD, Stephen Chung, MD, Robert H. Collins, MD, Xin Liu, PhD, Jian Xu, PhD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-141433

Published: 2020

Journal Articles

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

Yuxuan Liu, PhD, Jole Fiorito, PhD, Yulissa Gonzalez, Brian Estrella, PhD, Elisa Calcagno, PhD, Elisa Zuccarello, PhD, Howook Hwang, PhD, Barry Honig, PhD, Shixian Deng, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD, Ottavio Arancio, PhD, Jennifer E Amengual, MD

Blood (2019) 134 (Supplement_1): 4068.

https://doi.org/10.1182/blood-2019-125983

Published: 2019

Journal Articles

Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma

Yuxuan Liu, PhD, Jole Fiorito, PhD, Yulissa Gonzalez, Elisa Zuccarello, PhD, Elisa Calcagno, Adolfo Mazzeo, Nebiyu Ali Abshiru, PhD, Jeannie Camarillo, PhD, Neil L Kelleher, PhD, Changhong Qiao, Renu Nandakumar, PhD, Cremers Serge, PhD PharmD, Shixian Deng, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD, PhD, Ottavio Arancio, PhD, Jennifer E Amengual, MD

Blood (2018) 132 (Supplement 1): 37.

https://doi.org/10.1182/blood-2018-99-110447

Published: 2018

Journal Articles

Targeting the Epigenetic and Metabolic Vulnerabilities of Ezh2-Deficiency-Induced Myeloid Neoplasms

Zhimin Gu, PhD, Yuxuan Liu, PhD, Hui Cao, MS, Mingyi Chen, MD PhD, Yuannyu Zhang, PhD, Le Qi, Xin Liu, PhD, Kailong Li, PhD, Kathryn Dickerson, MD, Feng Cai, PhD, Weina Chen, MD PhD, Min Ni, PhD, Ralph Deberardinis, MD PhD, Jian Xu, PhD

Blood (2017) 130 (Supplement 1): 380.

https://doi.org/10.1182/blood.V130.Suppl_1.380.380

Published: 2017

Journal Articles

The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Jennifer E Amengual, MD, Renee Lichtenstein, Celeste Rojas, Ahmed Sawas, MD, Changchun Deng, MD PhD, Emily Lichtenstien, Karen Kahn, Jennifer Kimberly Lue, MD, Yuxuan Liu, PhD, Changhong Qiao, Renu Nandakumar, PhD, Serge Cremers, PhD, Owen A. O'Connor, MD PhD

Blood (2016) 128 (22): 1824.

https://doi.org/10.1182/blood.V128.22.1824.1824

Published: 2016

Journal Articles

Epigenetic Targeting with EZH2 and HDAC Inhibitors Is Synergistic in EZH2 Deregulated Lymphomas

Jennifer Kimberly Lue, MD, Sathyen A Prabhu, Yuxuan Liu, PhD, Owen A. O'Connor, MD PhD, Jennifer E Amengual, MD

Blood (2016) 128 (22): 839.

https://doi.org/10.1182/blood.V128.22.839.839

Published: 2016

Journal Articles

MYC-Dependent PI3K and MCL-1 Feedbacks Attenuate BET Inhibitors Activity in Diffuse Large B-Cell Lymphoma

Enrico Derenzini, MD PhD, Patrizia Mondello, MD MSc, Yuxuan Liu, PhD, Mary Scallion, Zahra Asgari, John Philip, Patrick Hilden, MS, Hakim Djaballah, PhD, Ouathek Ouerfelli, PhD, Elisa de Stanchina, PhD, Venkatraman Seshan, PhD, Ronald Hendrickson, PhD, Andrew D. Zelenetz, Anas Younes, MD

Blood (2016) 128 (22): 294.

https://doi.org/10.1182/blood.V128.22.294.294

Published: 2016

Journal Articles

Specific PML Isoforms and SATB1 Affect HLA Expression In Classical Hodgkin Lymphoma

Yuxuan Liu, Anke Van Den Berg, PhD, Bea Rutgers, Rianne Veenstra, Debora de Jong, Gertrud Kortman, Gustaaf van Imhoff, Lydia Visser, Arjan Diepstra, MD PhD

Blood (2013) 122 (21): 4234.

https://doi.org/10.1182/blood.V122.21.4234.4234

Published: 2013

Journal Articles

Strong HLA Class I Expression Is Positively Correlated with the Number of PML Nuclear Bodies and Negatively with the Percentage of SATB1 Positive HRS Cells in EBV+ Classical Hodgkin Lymphoma (cHL)

Yuxuan Liu, Lydia Visser, Rianne Veenstra, Bea Rutgers, Anke Van Den Berg, PhD, Arjan Diepstra, MD PhD

Blood (2012) 120 (21): 3633.

https://doi.org/10.1182/blood.V120.21.3633.3633

Published: 2012

NARROW

Dissecting the Interplay between Primary Central Nervous System Lymphoma Cells and the Microenvironment Using Single-Cell Transcriptomic Analysis

Prior Knowledge Integration Improves Relapse Prediction and Identifies Relapse Associated Mechanisms in Childhood B Cell Acute Lymphoblastic Leukemia

Enrichment in Metabolic Pathway Activation Corresponds to Immunoglobulin Gene Diversity across B Cell Developmental Stages in B-Lymphoblastic Leukemia

Uridine Synthesis Is the Metabolic Vulnerability in Relapse-Associated B-ALL Cells with Active Pre-BCR Signaling

Single-Cell Proteomic Analysis Defines Metabolic Heterogeneity in Response to Venetoclax in AML

Targeting Cell Adhesion Molecules in IDH Mutant Myeloid Malignances

First-in-Class Histone Acetyltransferase (HAT) Activator, YF2, Modulates Immune Evasion in DLBCL, Enhancing the Effects of Immune Checkpoint Blockade

Glucocorticoid-Resistant B-Cell Acute Lymphoblastic Leukemic Cells Can be Targeted By BCR-Signaling Inhibition

Inhibition of Pre-BCR Signaling Mediates a Metabolic Switch in B-Cell Progenitor Acute Lymphoblastic Leukemia

Histone Acetyltransferase (HAT) Activator, YF2, Modulates the p53:BCL6 Axis and Antigen Presentation in Diffuse Large B-Cell Lymphomas

Elucidating Mechanisms of Acquired Resistance to IDH Inhibition By Saturation Variant Screening of Base-Edited Leukemia Cells

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma

Targeting the Epigenetic and Metabolic Vulnerabilities of Ezh2-Deficiency-Induced Myeloid Neoplasms

The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Epigenetic Targeting with EZH2 and HDAC Inhibitors Is Synergistic in EZH2 Deregulated Lymphomas

MYC-Dependent PI3K and MCL-1 Feedbacks Attenuate BET Inhibitors Activity in Diffuse Large B-Cell Lymphoma

Specific PML Isoforms and SATB1 Affect HLA Expression In Classical Hodgkin Lymphoma

Strong HLA Class I Expression Is Positively Correlated with the Number of PML Nuclear Bodies and Negatively with the Percentage of SATB1 Positive HRS Cells in EBV+ Classical Hodgkin Lymphoma (cHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only